Previous clinical trials did not stratify patients by predicting SAS efficacy based on the expression of the GSH synthesis pathway, such as xCT and CGL expression, which may have resulted in a lack of efficacy. This evidence concerns the gene SLC7A11 and SATB2 associated disorder.